

Mary M Horowitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6942409/publications.pdf>

Version: 2024-02-01

187
papers

18,746
citations

18436

62
h-index

12558

132
g-index

191
all docs

191
docs citations

191
times ranked

12026
citing authors

#	ARTICLE	IF	CITATIONS
1	Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. <i>American Journal of Hematology</i> , 2023, 98, 140-147.	2.0	12
2	One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. <i>Haematologica</i> , 2022, 107, 1045-1053.	1.7	87
3	Adding Centralized Electronic Patient-Reported Outcome Data Collection to an Established International Clinical Outcomes Registry. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 112.e1-112.e9.	0.6	4
4	Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 109.e1-109.e8.	0.6	12
5	Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2022, 40, 356-368.	0.8	79
6	Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials. <i>Cytotherapy</i> , 2022, 24, 742-749.	0.3	2
7	HLA-DQ heterodimers in hematopoietic cell transplantation. <i>Blood</i> , 2022, 139, 3009-3017.	0.6	17
8	Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101 Open for Accrual June 2012 Open for Accrual June 2012. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 406.e1-406.e6.	0.6	4
9	Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 409.e1-409.e10.	0.6	26
10	Race and Survival in Unrelated Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 357.e1-357.e6.	0.6	9
11	Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology</i> , 2022, 9, e374-e384.	2.2	11
12	Are We Making PROGRESS in Preventing Graft-versus-Host Disease and Improving Clinical Outcomes? Impact of BMT CTN 1301 Study Results on Clinical Practice. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 419-425.	0.6	2
13	HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age. <i>Blood Advances</i> , 2022, 6, 4335-4346.	2.5	9
14	Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 8057-8057.	0.8	0
15	Incorporating patient-reported outcome data into a hematopoietic cell transplant survival calculator. <i>Journal of Clinical Oncology</i> , 2022, 40, 7045-7045.	0.8	0
16	Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 183.e1-183.e7.	0.6	6
17	Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia. <i>JAMA Oncology</i> , 2021, 7, 42.	3.4	51
18	Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. <i>Blood</i> , 2021, 137, 420-428.	0.6	119

#	ARTICLE	IF	CITATIONS
19	Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes—Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 483.e1-483.e6.	0.6	52
20	Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies. <i>Journal of Clinical Oncology</i> , 2021, 39, 534-544.	0.8	6
21	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 267.e1-267.e5.	0.6	6
22	Serious Adverse Events in Related Donors: A Report from the Related Donor Safe Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 352.e1-352.e5.	0.6	2
23	National Marrow Donor Program—Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2021, 39, 1971-1982.	0.8	90
24	Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2021, 39, 3328-3339.	0.8	72
25	The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 507-516.	0.6	26
26	Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 885-907.	0.6	12
27	Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation. <i>Cancer</i> , 2021, 127, 4339-4347.	2.0	4
28	Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials?. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab441.	0.4	3
29	A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 837.e1-837.e10.	0.6	0
30	Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation. <i>JAMA Oncology</i> , 2020, 6, e192974.	3.4	15
31	Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. <i>Lancet Haematology</i> , 2020, 7, e50-e60.	2.2	53
32	Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome. <i>JAMA Oncology</i> , 2020, 6, 486.	3.4	39
33	Health-Related Quality-of-Life Comparison of Adult Related and Unrelated HSC Donors: An RDSafe Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2365-2371.	2.0	6
34	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2181-2189.	2.0	51
35	Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1876-1885.	2.0	4
36	Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 5414-5424.	2.5	263

#	ARTICLE	IF	CITATIONS
37	Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e161-e166.	2.0	38
38	HLA-B Leader and Survivorship after HLA-Mismatched Unrelated Donor Transplantation. <i>Blood</i> , 2020, 136, 362-369.	0.6	20
39	Feasibility of Centralized Electronic Patient-Reported Outcome (ePRO) Collection By an Outcome Registry, a CIBMTR Study of Patients on the Centers for Medicaid & Medicare Coverage with Evidence Development (CMS CED) Myelodysplasia Protocol. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S66.	2.0	1
40	Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1312-1317.	2.0	49
41	Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. <i>Blood</i> , 2020, 135, 97-107.	0.6	56
42	Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. <i>Blood Advances</i> , 2020, 4, 467-476.	2.5	39
43	The Changing Landscape of Treatment in Acute Myeloid Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 343-354.	1.8	9
44	Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e177-e182.	2.0	378
45	Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8506-8506.	0.8	63
46	Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT). <i>Blood</i> , 2020, 136, 33-34.	0.6	0
47	Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2160-2166.	2.0	27
48	FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?. <i>Journal of Clinical Oncology</i> , 2019, 37, 1604-1607.	0.8	29
49	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1202). <i>Lancet Haematology</i> , 2019, 6, e132-e143.	2.2	200
50	Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 589-597.	0.8	184
51	Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries. <i>Bone Marrow Transplantation</i> , 2019, 54, 1179-1188.	1.3	51
52	Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. <i>Blood Advances</i> , 2019, 3, 875-883.	2.5	25
53	Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 699-711.	2.0	11
54	Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 955-964.	2.0	7

#	ARTICLE	IF	CITATIONS
55	Female Sex is Associated With Poor Health-related Quality of Life in Children at 12 Months Post-Hematopoietic Cell Transplantation. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 233-237.	0.3	8
56	Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. <i>Haematologica</i> , 2019, 104, 844-854.	1.7	13
57	Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucl (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US). <i>Blood</i> , 2019, 134, 764-764.	0.6	77
58	Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1049-1056.	2.0	98
59	Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. <i>Haematologica</i> , 2018, 103, 717-727.	1.7	38
60	Epidemiology and biology of relapse after stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1379-1389.	1.3	85
61	Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 932-937.	1.3	1
62	Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1274-1280.	2.0	46
63	Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. <i>BMC Cancer</i> , 2018, 18, 359.	1.1	15
64	Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1463-1470.	2.0	31
65	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
66	PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. <i>Cancer</i> , 2018, 124, 841-849.	2.0	38
67	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 521-528.	2.0	34
68	Patient HLA Germline Variation and Transplant Survivorship. <i>Journal of Clinical Oncology</i> , 2018, 36, 2524-2531.	0.8	12
69	Should an HLA-matched donor still be considered the perfect donor?. <i>Lancet Haematology</i> , 2018, 5, e388-e390.	2.2	4
70	Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. <i>Blood Advances</i> , 2018, 2, 2095-2103.	2.5	66
71	Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2145-2151.	2.0	14
72	A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. <i>Haematologica</i> , 2018, 103, 1915-1924.	1.7	34

#	ARTICLE	IF	CITATIONS
73	Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated. <i>Haematologica</i> , 2018, 103, 1708-1719.	1.7	8
74	Translation of Clinical Research into Practice: An Impact Assessment of the Results from the Blood and Marrow Transplant Clinical Trials Network Protocol 0201 on Unrelated Graft Source Utilization. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2204-2210.	2.0	11
75	Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. <i>BMC Cancer</i> , 2018, 18, 593.	1.1	28
76	Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology</i> , 2018, 5, e563-e598.	2.2	97
77	Risk Score for the Development of Venous Occlusive Disease after Allogeneic Hematopoietic Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2072-2080.	2.0	50
78	Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. <i>Cancer</i> , 2017, 123, 2025-2034.	2.0	48
79	Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2017, 35, 1154-1161.	0.8	495
80	Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1295-1302.	2.0	8
81	Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful. <i>Cancer</i> , 2017, 123, 4687-4700.	2.0	50
82	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e431-e442.	2.2	132
83	Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1714-1721.	2.0	24
84	Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. <i>Lancet Haematology</i> , 2017, 4, e325-e333.	2.2	72
85	Health-Related Quality of Life among Older Related Hematopoietic Stem Cell Donors (>60 Years) Is Equivalent to That of Younger Related Donors (18 to 60 Years): A Related Donor Safety Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 165-171.	2.0	12
86	Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?. <i>Journal of Oncology Practice</i> , 2017, 13, 798-806.	2.5	13
87	US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. <i>Blood Advances</i> , 2016, 1, 250-259.	2.5	142
88	Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 478-484.	0.9	39
89	Defibrotide for Treatment of Severe Venous Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1306-1312.	2.0	53
90	Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1440-1448.	2.0	44

#	ARTICLE	IF	CITATIONS
91	The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. <i>Blood</i> , 2016, 127, 260-267.	0.6	245
92	Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. <i>Blood</i> , 2016, 128, 1050-1058.	0.6	74
93	Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2256-2263.	2.0	20
94	Health-Related Quality of Life among Pediatric Hematopoietic Stem Cell Donors. <i>Journal of Pediatrics</i> , 2016, 178, 164-170.e1.	0.9	32
95	Practice Patterns and Preferences Among Hematopoietic Cell Transplantation Clinicians. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2092-2099.	2.0	6
96	Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT) Tj ETQq0 0.0 rgBT /Overlock 10	2.0	87
97	Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation. <i>JAMA Oncology</i> , 2016, 2, 1583.	3.4	110
98	A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. <i>Blood</i> , 2016, 128, 2561-2567.	0.6	174
99	The Impact of Palifermin Use on Hematopoietic Cell Transplant Outcomes in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1460-1466.	2.0	6
100	Global Use of Peripheral Blood vs Bone Marrow as Source of Stem Cells for Allogeneic Transplantation in Patients With Bone Marrow Failure. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 198.	3.8	18
101	Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 359-370.	2.0	127
102	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. <i>Blood</i> , 2015, 126, 1033-1040.	0.6	565
103	Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1815-1822.	2.0	13
104	Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 552-558.	2.0	12
105	Bone Marrow or Peripheral Blood for Reduced-Intensity Conditioning Unrelated Donor Transplantation. <i>Journal of Clinical Oncology</i> , 2015, 33, 364-369.	0.8	51
106	One million haemopoietic stem-cell transplants: a retrospective observational study. <i>Lancet Haematology</i> , 2015, 2, e91-e100.	2.2	329
107	Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1479-1487.	2.0	173
108	Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 640-645.	2.0	23

#	ARTICLE	IF	CITATIONS
109	Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. <i>Journal of Clinical Oncology</i> , 2015, 33, 4167-4175.	0.8	149
110	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1343-1359.	2.0	105
111	Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1“2 dose de-escalation study. <i>Lancet Haematology</i> , 2015, 2, e367-e375.	2.2	64
112	Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 266-274.	2.0	331
113	Recommendations for Donor Human Leukocyte Antigen Assessment and Matching for Allogeneic Stem Cell Transplantation: Consensus Opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 4-7.	2.0	83
114	Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 2020-2028.	3.2	98
115	Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age. <i>Blood</i> , 2015, 126, 193-193.	0.6	11
116	Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901. <i>Blood</i> , 2015, 126, LBA-8-LBA-8.	0.6	59
117	HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry. <i>New England Journal of Medicine</i> , 2014, 371, 339-348.	13.9	861
118	Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 662-667.	2.0	25
119	Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome after Allogeneic Stem Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network Protocol. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 858-864.	2.0	78
120	One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers. <i>New England Journal of Medicine</i> , 2014, 371, 1685-1694.	13.9	246
121	Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design, and Methods. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1566-1572.	2.0	24
122	Exercise and Stress Management Training Prior to Hematopoietic Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1530-1536.	2.0	78
123	Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2014, 124, 2596-2606.	0.6	228
124	Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. <i>Blood</i> , 2014, 123, 3664-3671.	0.6	730
125	Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. <i>Blood</i> , 2014, 124, 1372-1377.	0.6	178
126	Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. <i>Blood</i> , 2014, 124, 3221-3227.	0.6	92

#	ARTICLE	IF	CITATIONS
127	HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation. <i>Blood</i> , 2014, 124, 3996-4003.	0.6	146
128	Patient-Reported Quality of Life Is an Independent Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation: A Secondary Analysis from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. <i>Blood</i> , 2014, 124, 206-206.	0.6	8
129	Superiority of Pediatric Chemotherapy over Allogeneic Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult ALL in First Complete Remission: A Combined Analysis of Dana-Farber ALL Consortium and CIBMTR Cohorts. <i>Blood</i> , 2014, 124, 319-319.	0.6	6
130	Reduced Intensity Conditioning (RIC) with Rituximab Yields Excellent Outcomes after Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed Follicular Lymphoma (FL): A Phase II Multicenter Trial from the Blood and Marrow Transplant Network (BMT CTN 0701). <i>Blood</i> , 2014, 124, 682-682.	0.6	3
131	Clinical Relevance of HLA Supertype Matching after Myeloablative Conditioning 7/8 Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Study. <i>Blood</i> , 2014, 124, 2572-2572.	0.6	0
132	Baseline Symptoms, Female Sex, and Younger Age Are Correlated with Higher Levels of Peri-Collection Pain, Symptoms, and Persistent Discomfort One Year after Related Donor BM and PBSC Donation: An Analysis of the Related Donor Safety Study (RDSafe). <i>Blood</i> , 2014, 124, 3847-3847.	0.6	0
133	Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 2662-2670.	0.8	265
134	Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1662-1668.	0.8	161
135	Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). <i>Blood</i> , 2013, 122, 1974-1982.	0.6	92
136	Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors. <i>New England Journal of Medicine</i> , 2012, 367, 1487-1496.	13.9	762
137	Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. <i>Blood</i> , 2012, 119, 3908-3916.	0.6	228
138	Comparative Outcomes of Donor Graft CD34 ⁺ Selection and Immune Suppressive Therapy As Graft-Versus-Host Disease Prophylaxis for Patients With Acute Myeloid Leukemia in Complete Remission Undergoing HLA-Matched Sibling Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 3194-3201.	0.8	143
139	Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 861-873.	2.0	53
140	Does matched unrelated donor transplantation have the same outcome as matched sibling transplantation in unselected patients?. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 483-486.	0.7	23
141	MHC-Resident Variation Affects Risks After Unrelated Donor Hematopoietic Cell Transplantation. <i>Science Translational Medicine</i> , 2012, 4, 144ra101.	5.8	55
142	Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 366, 1770-1781.	13.9	1,024
143	The Outcome of Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) in Adults ≥65 Years of Age: First Report of the Coverage with Evidence Development (CED) in Medicare Beneficiaries. <i>Blood</i> , 2012, 120, 1983-1983.	0.6	3
144	A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502. <i>Blood</i> , 2012, 120, 230-230.	0.6	14

#	ARTICLE	IF	CITATIONS
145	Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402. <i>Blood</i> , 2012, 120, 739-739.	0.6	19
146	Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complete Response or First Partial Response. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1051-1057.	2.0	85
147	Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. <i>Lancet Oncology</i> , The, 2011, 12, 1195-1203.	5.1	263
148	Impact of immune modulation with anti-CD28 antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. <i>Blood</i> , 2011, 117, 6963-6970.	0.6	322
149	Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2011, 29, 2230-2239.	0.8	530
150	Review of Stem-Cell Transplantation for Myelodysplastic Syndromes in Older Patients in the Context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome Emanating From the Centers for Medicare and Medicaid Services. <i>Journal of Clinical Oncology</i> , 2011, 29, 566-572.	0.8	31
151	Increased Incidence of Chronic Graft-Versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial. <i>Blood</i> , 2011, 118, 1-1.	0.6	24
152	Access to hematopoietic stem cell transplantation. <i>Cancer</i> , 2010, 116, 3469-3476.	2.0	124
153	Transplant Conditioning Regimens and Outcomes After Allogeneic Hematopoietic Cell Transplantation (HCT) in Children and Adolescents with Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2010, 116, 3506-3506.	0.6	1
154	Effect of Stem Cell Source From Unrelated Donors on Transplant Outcomes in Severe Aplastic Anemia (SAA): a Comparison of Unrelated Bone Marrow (BM) and Peripheral Blood Progenitor Cells (PBPC). <i>Blood</i> , 2010, 116, 531-531.	0.6	0
155	High-resolution typing for unrelated donor transplantation: How far do we go?. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 537-541.	0.7	20
156	Defining the Intensity of Conditioning Regimens: Working Definitions. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1628-1633.	2.0	1,419
157	Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. <i>Blood</i> , 2009, 114, 511-517.	0.6	217
158	Outcomes following HSCT Using Fludarabine, Busulfan, and Thymoglobulin: A Matched Comparison to Allogeneic Transplants Conditioned with Busulfan and Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 993-1003.	2.0	89
159	Use of biological assignment in hematopoietic stem cell transplantation clinical trials. <i>Clinical Trials</i> , 2008, 5, 607-616.	0.7	21
160	Donor-Recipient Matching at the HLA-C Locus and Early Outcomes after Unrelated Umbilical Cord Blood Transplant (UCBT). <i>Blood</i> , 2008, 112, 153-153.	0.6	2
161	Similar 5-Year Survival after Peripheral Blood Autotransplants (AutoPB) Versus HLA Matched Sibling Myeloablative Transplants (AlloBMT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1). <i>Blood</i> , 2008, 112, 2168-2168.	0.6	3
162	The Clinical Significance of Matching for Alleles at the Low Expression HLA Loci DP, DQ and DRB3/4/5 in Unrelated Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 561-561.	0.6	4

#	ARTICLE	IF	CITATIONS
163	Biologic Assignment Clinical Trials in Hematopoietic Stem Cell Transplantation (HSCT) for Multiple Myeloma: Baseline Characteristics by Treatment Allocation from BMT CTN 0102 According to Availability of an HLA-Matched Sibling Donor.. Blood, 2007, 110, 3028-3028.	0.6	1
164	Rapid Transport and Infusion of Hematopoietic Stem Cells Can Improve Outcome after Unrelated Donor Transplant.. Blood, 2007, 110, 3063-3063.	0.6	1
165	Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood, 2006, 108, 4288-4290.	0.6	157
166	Evaluation of Hematopoietic Stem Cell Donors. Hematology American Society of Hematology Education Program, 2005, 2005, 469-475.	0.9	61
167	Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood, 2005, 105, 1408-1416.	0.6	144
168	Outcome of Bone Marrow Transplantation for Myelofibrosis.. Blood, 2005, 106, 170-170.	0.6	11
169	Use of Peripheral Blood Grafts Is Associated with Increased Acute and Chronic Graft-Versus-Host Disease without Improved Survival after Unrelated Donor Transplantation.. Blood, 2005, 106, 443-443.	0.6	4
170	The Likelihood of Hematopoietic Stem Cell Transplantation (HCT) in the United States: Implications for Umbilical Cord Blood Storage.. Blood, 2005, 106, 1330-1330.	0.6	4
171	A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood, 2004, 104, 579-585.	0.6	638
172	Matched Pairs Analysis of IV vs. PO Busulfan as a Conditioning Agent Prior to Transplantation.. Blood, 2004, 104, 349-349.	0.6	8
173	Impact of Prior Pregnancy on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2004, 104, 1638-1638.	0.6	0
174	Multi-state models and outcome prediction in bone marrow transplantation. Statistics in Medicine, 2001, 20, 1871-1885.	0.8	70
175	Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. British Journal of Haematology, 1999, 104, 392-396.	1.2	110
176	Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation. New England Journal of Medicine, 1999, 341, 14-21.	13.9	666
177	Adoptive Immunotherapy for Leukemia: Donor Lymphocytes Transduced with the Herpes Simplex Thymidine Kinase Gene for Remission Induction. Human Gene Therapy Research Institute, Des Moines, Iowa, and Northwestern University School of Medicine, Chicago, Illinois. Human Gene Therapy, 1998, 9, 115-134.	1.4	38
178	IBMTR Severity INDEX FOR GRADING ACUTE GRAFTâ€VERSUSâ€HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE. British Journal of Haematology, 1997, 97, 855-864.	1.2	605
179	Survival of patients with chronic myelogenous leukaemia relapsing after bone marrow transplantation: comparison with patients receiving conventional chemotherapy. British Journal of Haematology, 1997, 99, 23-29.	1.2	7
180	Allogeneic marrow grafts from donors with congenital chromosomal abnormalities in marrow cells. British Journal of Haematology, 1995, 90, 595-601.	1.2	7

#	ARTICLE	IF	CITATIONS
181	Cox Regression in a Markov Renewal Model: An Application to the Analysis of Bone Marrow Transplant Data. <i>Journal of the American Statistical Association</i> , 1994, 89, 867-877.	1.8	54
182	Duration of Response to Intramuscular Versus Low Dose Intradermal Hepatitis B Booster Immunization. <i>Infection Control and Hospital Epidemiology</i> , 1991, 12, 226-230.	1.0	4
183	Use of A Clinical Data Registry to Evaluate Medical Technologies: Experience from the International Bone Marrow Transplant Registry. <i>International Journal of Technology Assessment in Health Care</i> , 1991, 7, 182-193.	0.2	10
184	AUTOTRANSPLANTS IN ACUTE LEUKAEMIA. <i>British Journal of Haematology</i> , 1991, 78, 135-137.	1.2	12
185	Risk factors for interstitial pneumonia following bone marrow transplantation for severe aplastic anaemia. <i>British Journal of Haematology</i> , 1989, 71, 535-543.	1.2	62
186	Uses and Growth of Hematopoietic Cell Transplantation. , 0, , 15-21.		14
187	Cox Regression in a Markov Renewal Model: An Application to the Analysis of Bone Marrow Transplant Data. , 0, .		13